Drug Type Antibody drug conjugate (ADC) |
Synonyms MEDI 7247, MEDI-7247 |
Target |
Mechanism ASCT2 inhibitors(solute carrier family 1 member 5 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H36N4O6 |
InChIKeyYMTZZJOPSATRTO-GOTSBHOMSA-N |
CAS Registry1595275-71-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 20 Dec 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 20 Dec 2018 | |
Colorectal Cancer | Phase 1 | US | 20 Dec 2018 | |
Colorectal Cancer | Phase 1 | CA | 20 Dec 2018 | |
Metastatic castration-resistant prostate cancer | Phase 1 | US | 20 Dec 2018 | |
Metastatic castration-resistant prostate cancer | Phase 1 | CA | 20 Dec 2018 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | US | 20 Dec 2018 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | CA | 20 Dec 2018 | |
Small Cell Lung Cancer | Phase 1 | US | 20 Dec 2018 | |
Small Cell Lung Cancer | Phase 1 | CA | 20 Dec 2018 |
Phase 1 | Hematologic Neoplasms ASCT2 expression | 67 | prwpzslzuz(csjalitsxj) = lfvflbxeug hapdfpwxvq (ivzbgwpvem ) | Negative | 29 Apr 2024 |